Histone Antibody, IgG
Histone antibodies are autoantibodies targeting histone proteins, which are integral components of chromatin structure within cell nuclei. Histones are classified into five distinct types: H1, H2A, H2B, H3, and H4. Autoantibodies directed against histone proteins may target individual histones or complexes of multiple histones. Notably, anti-histone H1 antibodies are strongly associated with severe systemic lupus erythematosus (SLE), whereas antibodies directed against the histone complex H2A–H2B predominantly occur in drug-induced lupus erythematosus (DILE).
In systemic lupus erythematosus, defective clearance of apoptotic cells leads to the persistent presence of histone-DNA complexes. The immune system erroneously recognizes these complexes as foreign antigens, resulting in the production of autoantibodies by B-cells. Immune complex deposition in organs such as the kidneys, joints, and central nervous system contributes significantly to clinical manifestations like lupus nephritis, polyarthritis, and neuropsychiatric lupus. Approximately 50–70% of patients with systemic lupus erythematosus exhibit histone antibody positivity.
Drug-induced lupus erythematosus arises when certain medications (e.g., hydralazine, procainamide, isoniazid, minocycline, and phenytoin) alter histone structures, triggering autoimmune responses against these modified histones. Histone antibody positivity is found in over 95% of patients with drug-induced lupus. A crucial differentiating feature between DILE and classic SLE is the presence or absence of anti-double stranded DNA (anti-dsDNA) antibodies. While anti-dsDNA antibodies are highly characteristic of classic SLE, they are usually absent or significantly less prevalent in drug-induced lupus.
- Diagnosis and monitoring of drug-induced lupus erythematosus
- As an aid in the diagnosis and monitoring of systemic lupus erythematosus
- Differential diagnosis of lupus erythematosus from other autoimmune rheumatic diseases
- Drug-induced lupus erythematosus
- Systemic lupus erythematosus
- Rheumatoid arthritis
- Sjogren’s syndrome
- Systemic sclerosis
Decreased in:
- Systematic Lupus Erythematosus in remission
- Drug-induced lupus after drug withdrawal
Negative: < or = 0.9 U
Weak positive: 1.0 – 1.5 U
Moderate positive: 1.6 – 2.5 U
Strong positive: > or = 2.6 U
Immunoassay, enzyme immunoassay, enzyme-linked immunosorbent assay (ELISA).
Serum (SST Tube).
Stability
- Ambient: 3-5 days
- Refrigerated: 7 days
- Frozen: 30 days.
- J Vis Exp. 2017 Aug 1;(126):55912. [PMID: 28809825]
- Clin Exp Rheumatol. 1989 May-Jun;7(3):265-71. [PMID: 2758706]
- J Invest Dermatol. 1999 May;112(5):711-5. [PMID: 10233761]
- Int J Mol Sci. 2019 Jun 25;20(12):3093. [PMID: 31242568]
- J Clin Invest. 1991 Aug;88(2):680-90. [PMID: 1864977]